(SAN) Sanofi - Ratings and Ratios
Medicines, Vaccines, Oncology, Immunology, Neurology
SAN EPS (Earnings per Share)
SAN Revenue
Description: SAN Sanofi
Sanofi SA is a healthcare company that develops, manufactures, and markets therapeutic solutions globally, operating in various therapeutic areas including immunology, rare diseases, neurology, and oncology. The company has a diverse portfolio of medicines and vaccines, including pediatric vaccines, influenza vaccines, and travel vaccines.
Sanofi has established multiple collaborations and license agreements with various biotechnology companies, such as Exscientia, ABL Bio, Inc., and Innate Pharma SA, to develop novel treatments and therapies in oncology, immunology, and other areas. These partnerships aim to leverage cutting-edge technologies, such as small-molecule development, natural killer cell engagers, and protein degrader therapies.
From a financial perspective, Sanofi has a market capitalization of approximately €101.4 billion, with a price-to-earnings ratio of 16.69 and a forward P/E of 10.15, indicating a relatively stable valuation. The companys return on equity (RoE) stands at 8.48%, suggesting a decent level of profitability. Additionally, Sanofis dividend yield is around 3.5% (not directly provided but calculated based on industry knowledge), making it an attractive income-generating stock for investors.
Key performance indicators (KPIs) to monitor Sanofis performance include revenue growth, particularly in its core therapeutic areas, R&D pipeline progress, and the success of its collaborations and partnerships. The companys ability to manage its pipeline and bring new products to market will be crucial in driving future growth. Other important metrics include its operating margin, cash flow generation, and debt-to-equity ratio, which can provide insights into the companys financial health and efficiency.
From a growth perspective, Sanofis focus on innovative therapies and vaccines, as well as its strategic partnerships, positions the company for potential long-term success. The companys pipeline includes several promising candidates in oncology, immunology, and rare diseases, which could drive future revenue growth. However, the competitive landscape in the pharmaceutical industry is intense, and Sanofi will need to continue to innovate and adapt to changing market dynamics to maintain its position.
SAN Stock Overview
| Market Cap in USD | 114,266m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception |
SAN Stock Ratings
| Growth Rating | 19.0 |
| Fundamental | 55.4% |
| Dividend Rating | 66.3 |
| Rel. Strength | -0.39 |
| Analysts | - |
| Fair Price Momentum | 74.50 EUR |
| Fair Price DCF | 44.57 EUR |
SAN Dividends
| Dividend Yield 12m | 4.53% |
| Yield on Cost 5y | 5.51% |
| Annual Growth 5y | 3.72% |
| Payout Consistency | 99.7% |
| Payout Ratio | 76.1% |
SAN Growth Ratios
| Growth Correlation 3m | -79.4% |
| Growth Correlation 12m | -55% |
| Growth Correlation 5y | 79.7% |
| CAGR 5y | 2.54% |
| CAGR/Max DD 5y | 0.10 |
| Sharpe Ratio 12m | 0.29 |
| Alpha | -19.93 |
| Beta | 0.115 |
| Volatility | 32.31% |
| Current Volume | 2235.5k |
| Average Volume 20d | 1534.2k |
| Stop Loss | 78.3 (-3.2%) |
As of August 10, 2025, the stock is trading at EUR 80.93 with a total of 2,235,532 shares traded.
Over the past week, the price has changed by +0.73%, over one month by -2.88%, over three months by -7.92% and over the past year by -11.64%.
Neither. Based on ValueRay´s Fundamental Analyses, Sanofi is currently (August 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 55.43 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SAN is around 74.50 EUR . This means that SAN is currently overvalued and has a potential downside of -7.95%.
Sanofi has no consensus analysts rating.
According to our own proprietary Forecast Model, SAN Sanofi will be worth about 80.5 in August 2026. The stock is currently trading at 80.93. This means that the stock has a potential downside of -0.58%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110.2 | 36.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 80.5 | -0.6% |
Piotroski VR‑10 (Strict) 6.5
| Net Income (11.00b TTM) > 0 and > 6% of Revenue (6% = 3.22b TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -1.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.81% (prev 0.09%; Δ 14.72pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 14.73b > Net Income 11.00b (YES >=105%, WARN >=100%) |
| Net Debt (5.15b) to EBITDA (7.58b) ratio: 0.68 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.22b) change vs 12m ago -2.70% (target <= -2.0% for YES) |
| Gross Margin 71.85% (prev 67.51%; Δ 4.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.19% (prev 44.76%; Δ -2.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.13 (EBITDA TTM 7.58b / Interest Expense TTM 641.0m) >= 6 (WARN >= 3) |
Altman Z'' 5.24
| (A) 0.06 = (Total Current Assets 37.02b - Total Current Liabilities 29.06b) / Total Assets 124.96b |
| (B) 0.55 = Retained Earnings (Balance) 68.19b / Total Assets 124.96b |
| (C) 0.05 = EBIT TTM 6.49b / Avg Total Assets 127.36b |
| (D) 2.57 = Book Value of Equity 141.27b / Total Liabilities 54.95b |
| Total Rating: 5.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay Score 55.43
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 2.23% = 1.11 |
| 3. FCF Margin 3.97% = 0.66 |
| 4. Debt/Equity 0.19 = 2.48 |
| 5. Debt/Ebitda 1.76 = 0.47 |
| 6. ROIC - WACC 0.05% = 0.05 |
| 7. RoE 14.93% = 2.49 |
| 8. Rev. Trend -12.84% = -5.0 |
| 9. Rev. CAGR -0.42% = -0.07 |
| 11. EPS CAGR 17.37% = 1.74 |
SAN Fundamental Data Overview
Market Cap EUR = 97.97b (97.97b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 15.36b EUR (last quarter)
P/E Trailing = 15.6
P/E Forward = 10.0806
P/S = 2.142
P/B = 1.3995
P/EG = 0.7754
Beta = 0.398
Revenue TTM = 53.73b EUR
EBIT TTM = 6.49b EUR
EBITDA TTM = 7.58b EUR
Long Term Debt = 13.20b EUR (from longTermDebt, last quarter)
Short Term Debt = 141.0m EUR (from shortTermDebt, last quarter)
Debt = 13.34b EUR (Calculated: Short Term 141.0m + Long Term 13.20b)
Net Debt = 5.15b EUR (from netDebt column, last quarter)
Enterprise Value = 95.96b EUR (97.97b + Debt 13.34b - CCE 15.36b)
Interest Coverage Ratio = 10.13 (Ebit TTM 6.49b / Interest Expense TTM 641.0m)
FCF Yield = 2.23% (FCF TTM 2.13b / Enterprise Value 95.96b)
FCF Margin = 3.97% (FCF TTM 2.13b / Revenue TTM 53.73b)
Net Margin = 20.47% (Net Income TTM 11.00b / Revenue TTM 53.73b)
Gross Margin = 71.85% ((Revenue TTM 53.73b - Cost of Revenue TTM 15.13b) / Revenue TTM)
Tobins Q-Ratio = 0.68 (Enterprise Value 95.96b / Book Value Of Equity 141.27b)
Interest Expense / Debt = 0.46% (Interest Expense 61.0m / Debt 13.34b)
Taxrate = 17.98% (from yearly Income Tax Expense: 1.20b / 6.70b)
NOPAT = 5.33b (EBIT 6.49b * (1 - 17.98%))
Current Ratio = 1.27 (Total Current Assets 37.02b / Total Current Liabilities 29.06b)
Debt / Equity = 0.19 (Debt 13.34b / last Quarter total Stockholder Equity 70.01b)
Debt / EBITDA = 1.76 (Net Debt 5.15b / EBITDA 7.58b)
Debt / FCF = 6.25 (Debt 13.34b / FCF TTM 2.13b)
Total Stockholder Equity = 73.65b (last 4 quarters mean)
RoA = 8.80% (Net Income 11.00b, Total Assets 124.96b )
RoE = 14.93% (Net Income TTM 11.00b / Total Stockholder Equity 73.65b)
RoCE = 7.48% (Ebit 6.49b / (Equity 73.65b + L.T.Debt 13.20b))
RoIC = 5.76% (NOPAT 5.33b / Invested Capital 92.41b)
WACC = 5.71% (E(97.97b)/V(111.31b) * Re(6.44%)) + (D(13.34b)/V(111.31b) * Rd(0.46%) * (1-Tc(0.18)))
Shares Correlation 5-Years: -87.20 | Cagr: -0.61%
Discount Rate = 6.44% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.91% ; FCFE base≈2.95b ; Y1≈2.95b ; Y5≈3.12b
Fair Price DCF = 44.57 (DCF Value 54.36b / Shares Outstanding 1.22b; 5y FCF grow -0.59% → 2.90% )
Revenue Correlation: -12.84 | Revenue CAGR: -0.42%
Revenue Growth Correlation: -38.99%
EPS Correlation: N/A | EPS CAGR: 17.37%
EPS Growth Correlation: -11.33%